STELLAR-305 is a randomized, double-blind, phase 2/3 study that will evaluate the efficacy and safety of zanzalintinib plus pembrolizumab vs pembrolizumab and placebo in patients with previously untreated, PD-L1-positive, recurrent or metastatic SCCHN. The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.